Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial

Kim, Jwa Hoon; Ryu, Min‐Hee; Park, Young Soo; Ma, Jungeun; Lee, Sun Young; Kim, Deokhoon; Kang, Yoon‐Koo

doi:10.1186/s12885-022-09488-2

Cited by 22 publications

(24 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kim et al investigated predictors for nivolumab. 14 In their report, normal serum sodium and low neutrophil lymphocyte ratio (NLR) were used as predictors of nivolumab response. 14 In the present case, the patient showed normal sodium (140 mEq/L), and low NLR (0.82), which suggested that the patient was a good responder to nivolumab.…”

Section: Discussionmentioning

confidence: 99%

“…14 In their report, normal serum sodium and low neutrophil lymphocyte ratio (NLR) were used as predictors of nivolumab response. 14 In the present case, the patient showed normal sodium (140 mEq/L), and low NLR (0.82), which suggested that the patient was a good responder to nivolumab. 15,16 Regarding pathological findings, this case did not have specific findings regarding nivolumab.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Complete Response of Recurrent Gastric Cancer after Third-line CPT-11 Chemotherapy

2023

View full text Add to dashboard Cite

A 75-year-old man underwent distal gastrectomy for advanced gastric cancer in September 2018. During the adjuvant chemotherapy, computed tomography (CT) revealed recurrence sites in the liver and para-aortic lymph nodes. Therefore, chemotherapy was initiated. After first-line (capecitabine with oxaliplatin) and second-line (paclitaxel with ramucirumab) treatments, nivolumab was used as third-line chemotherapy. This treatment showed a strong effect against the tumor. However, following an immunerelated adverse effect (irAE) because of nivolumab, the therapy was halted. The irAE was diagnosed with central adrenal insufficiency that was controllable by oral intake of steroids. CPT-11 was started and showed a similarly strong effect to that observed for nivolumab. Eventually, the recurrent tumor lesions became too small to be detected by CT. We discontinued CPT-11 at the request of the patient. Even after discontinuation, no recurrent sites have been observed, allowing us to declare a case of clinical complete response (cCR). In conclusion, even if irAEs occur in a patient, continuing chemotherapy should be considered. However, if cCR is achieved, discontinuation of chemotherapy might be a strategic treatment option.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Clinical Complete Response of Recurrent Gastric Cancer after Third-line CPT-11 Chemotherapy

2023

View full text Add to dashboard Cite

show abstract

“…The 5-year survival rate of patients with advanced gastric cancer was only 5% and 20%, and the median overall survival rate was 10 months. Advanced gastric cancer has a poor prognosis and limited therapeutic options ( 89 , 105 , 106 ). Therefore, it is urgent to explore some new molecular targets and treatments.…”

Section: Pd-1/pd-l1 and Inhibitors In Human Solid Cancersmentioning

confidence: 99%

“…Advanced gastric cancer has a poor prognosis and limited therapeutic options (89,105,106). Therefore, it is urgent to explore some new molecular targets and treatments.…”

Section: Gastric Cancermentioning

confidence: 99%

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

et al. 2022

View full text Add to dashboard Cite

Programmed cell death protein-1 (PD-1) is a checkpoint receptor expressed on the surface of various immune cells. PD-L1, the natural receptor for PD-1, is mainly expressed in tumor cells. Studies have indicated that PD-1 and PD-L1 are closely associated with the progression of human cancers and are promising biomarkers for cancer therapy. Moreover, the interaction of PD-1 and PD-L1 is one of the important mechanism by which human tumors generate immune escape. This article provides a review on the role of PD-L1/PD-1, mechanisms of immune response and resistance, as well as immune-related adverse events in the treatment of anti-PD-1/PD-L1 immunotherapy in human cancers. Moreover, we summarized a large number of clinical trials to successfully reveal that PD-1/PD-L1 Immune-checkpoint inhibitors have manifested promising therapeutic effects, which have been evaluated from different perspectives, including overall survival, objective effective rate and medium progression-free survival. Finally, we pointed out the current problems faced by PD-1/PD-L1 Immune-checkpoint inhibitors and its future prospects. Although PD-1/PD-L1 immune checkpoint inhibitors have been widely used in the treatment of human cancers, tough challenges still remain. Combination therapy and predictive models based on integrated biomarker determination theory may be the future directions for the application of PD-1/PD-L1 Immune-checkpoint inhibitors in treating human cancers.

show abstract

“…Several recent studies have revealed relationships of immunerelated markers with the treatment response, prognosis, and survival rate in GC treated with chemotherapy. The addition of molecular markers to TNM staging provides additional information regarding GC (11)(12)(13). Cancer progression depends on crosstalk between cancer cells and the immune system (14).…”

Section: Introductionmentioning

confidence: 99%

Prognostic significances of PD-L1- and CTLA-4-positive T cells and positive correlations of immunosuppressive marker expression between cancer tissue and peripheral blood in patients with gastric cancer

et al. 2023

View full text Add to dashboard Cite

IntroductionAlthough tumor, node, metastasis (TNM) staging has been used for prognostic assessment of gastric cancer (GC), the prognosis may vary among patients with the same TNM stage. Recently, the TNM-Immune (TNM-I) classification staging system has been used for prognostic assessment of colorectal cancer based on intra-tumor T-cell status, which is a superior prognostic factor compared with the American Joint Committee on Cancer staging manual. However, an immunoscoring system with prognostic significance for GC has not been established.MethodHere, we evaluated immune phenotypes in cancer and normal tissues, then examined correlations between tissues and peripheral blood. GC patients who underwent gastrectomy at Seoul St. Mary’s Hospital between February 2000 and May 2021 were included. We collected 43 peripheral blood samples preoperatively and a pair of gastric mucosal samples postoperatively, including normal and cancer mucosa, which did not influence tumor diagnosis and staging. Tissue microarray samples of GC were collected from 136 patients during surgery. We investigated correlations of immune phenotypes between tissues and peripheral blood using immunofluorescence imaging and flow cytometry, respectively. GC mucosa exhibited an increased number of CD4+ T cells, as well as increased expression levels of immunosuppressive markers (e.g., programmed death-ligand-1 [PD-L1], cytotoxic T lymphocyte antigen-4 [CTLA-4], and interleukin-10), in CD4+ T cells and non-T cells. ResultThe expression levels of immunosuppressive markers were significantly increased in cancer tissues and peripheral blood mononuclear cells. In gastric mucosal tissues and peripheral blood of GC patients, similar immunosuppression phenotypes were observed, including increased numbers of PD-L1- and CTLA-4-positive T cells. DiscussionTherefore, peripheral blood analysis may be an important tool for prognostic assessment of GC patients.

show abstract

Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial

Cited by 22 publications

References 36 publications

Clinical Complete Response of Recurrent Gastric Cancer after Third-line CPT-11 Chemotherapy

Clinical Complete Response of Recurrent Gastric Cancer after Third-line CPT-11 Chemotherapy

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

Prognostic significances of PD-L1- and CTLA-4-positive T cells and positive correlations of immunosuppressive marker expression between cancer tissue and peripheral blood in patients with gastric cancer

Contact Info

Product

Resources

About